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Circulating microRNAs as minimally invasive biomarkers for 
cancer theragnosis and prognosis
William C. S. Cho*
Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong
Novel cancer biomarker discovery is urgently needed for cancer theragnosis and prognosis, 
and among the many possible types of samples, blood is regarded to be ideal for this discovery 
as it can be collected easily in a minimally invasive manner. Results of the past few years have 
ascertained the quantification of microRNA (miRNA) as a promising approach for the detection 
and prognostication of cancer. Indeed, an increasing number of studies have shown that 
circulating cancer-associated miRNAs are readily measured in plasma or serum and they can 
robustly discriminate cancer patients from healthy controls, as well as distinguishing between 
good-prognosis and poor-prognosis patients. Furthermore, recent findings also suggest the 
potential of circulating miRNAs in the screening, monitoring, and treatment of cancer. This article 
summarizes the most significant and latest discoveries of original researches on circulating 
miRNAs involvement in cancer, focusing on the potential of circulating miRNAs as minimally 
invasive biomarkers for cancer theragnosis and prognosis.
Keywords: blood-based biomarker, cancer, circulating microRNA, minimally invasive biomarker, molecular tumor marker, 
oncomir, prognosis, theragnosis
Role of ciRculating miRnas in the moleculaR pathogenesis 
and pRogRession of canceR
Previous study has suggested that profiling of circulating miRNAs 
may help identify promising biomarkers of various pathologic 
conditions (Ji et al., 2009). In the study of chronic lymphocytic 
leukemia (CLL), low expression of miR-29b, miR-29c, miR-181 
family, and miR-223 were found to be strongly associated with 
disease progression in CLL cases harboring 17p deletion, whereas 
high expression of miR-181a in those harboring trisomy 12 sug-
gested more aggressive disease. These biomarkers may be clinically 
useful to assess the tumor behavior in CLL (Visone et al., 2009). A 
pilot study also evaluated the circulating miRNAs associated with 
tumor progression in breast cancer patients. It provided evidence 
that the relative concentration of miR-155 in serum significantly 
discriminated primary breast cancer patients from healthy women. 
Within the primary breast cancer cohort, patients at advanced 
tumor stages had significantly higher miR-34a than patients at 
early tumor stages. In the metastatic patients, miR-10b, miR-34a, 
and miR-155 correlated with the presence of overt metastases 
(Roth et al., 2010).
diagnostic and pRognostic value of ciRculating miRnas foR 
canceR
The releases of miRNAs from malignant cells in body fluids are can-
didate diagnostics for a variety of cancers. A recent study reported 
that the release of miRNAs from breast cancer cells into blood, milk, 
and ductal fluids was selective and that the selection of released 
miRNAs might correlate with malignancy. In particular, the bulk 
of miR-451 and miR-1246 produced by malignant mammary epi-
thelial cells was released into the blood, but the majority of these 
miRNAs produced by non-malignant mammary epithelial cells was 
intRoduction
In terms of suffering and death, cancer is tragic yet partly prevent-
able. The developments of valid biomarkers to prevent, detect, and 
treat this devastating disease can save millions of lives. However, the 
establishment of clinically validated biomarkers for cancer remains 
an insurmountable task despite the advances in molecular biology. 
An ideal tumor marker should be measured easily, reliably, and cost-
effectively using a minimally invasive assay with high analytical sen-
sitivity and specificity. Results of the last few years have ascertained 
the quantification of microRNA (miRNA) as a promising approach 
for the detection and prognostication of cancer (Cho, 2007, 2010a). 
Nevertheless, it remains uncertain whether circulating miRNA is 
tumor specific and whether systemic miRNA analysis has utility in 
cancer management. Indeed, miRNA is present in human blood in a 
remarkably stable form protected from endogenous RNase activity 
(Mitchell et al., 2008). An increasing number of studies have shown 
that circulating cancer-associated miRNAs (oncomirs) are readily 
measured in plasma or serum and they can robustly discriminate 
cancer patients from healthy controls. This article summarizes the 
most significant and latest findings of original researches on circu-
lating miRNAs involvement in cancer, focusing on the potential of 
circulating miRNAs as minimally invasive biomarkers for cancer 
theragnosis and prognosis (Table 1).
miRna and canceR
MicroRNAs are emerging as important modulators in cellular path-
ways, and they appear to play a key role in tumorigenesis (Cho, 
2010b). Numerous studies have documented the implications of 
miRNAs in nearly every carcinogenesis process, including tumor 
development, apoptosis, invasion, and metastasis, as well as anti-
cancer drug resistance (Cho, 2009, 2010c).
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retained. Their findings suggest that the selective release of miRNA 
is an important consideration for the identification of circulating 
miRNA as molecular tumor marker (Pigati et al., 2010).
An investigation of plasma miRNAs in colorectal cancer (CRC) 
indicated that miR-29a and miR-92a could significantly discrimi-
nate neoplasia from healthy controls, and combined analyses using 
these two miRNAs revealed higher sensitivity and specificity. These 
data suggest that plasma miR-29a and miR-92a have strong poten-
tial as minimally invasive biomarkers for the detection of CRC 
(Huang et al., 2010). Another study found that plasma miR-92 
also had significant diagnostic value for CRC. This biomarker 
could significantly differentiate CRC from gastric cancer, inflam-
matory bowel disease, and normal subjects, suggesting it to be a 
potential minimally invasive molecular marker for CRC diagnosis 
(Ng et al., 2009).
In the analysis of serum miRNAs, most pancreatic cancers dis-
played hypomethylation and over-expression of miR-200a and 
miR-200b, silencing of SIP1 by promoter methylation, and retention 
of E-cadherin expression. The elevated serum levels of miR-200a 
and miR-200b in most patients with pancreatic cancer may have 
diagnostic utility (Li et al., 2010). On the other hand, profiling of 
miR-21, miR-155, miR-196a, and miR-210 showed that miRNA pro-
filing in plasma could also differentiate pancreatic adenocarcinoma 
patients from healthy controls. These results show the feasibility 
of developing plasma miRNA profiling as a sensitive and specific 
blood-based biomarker assay for pancreatic cancer that has the 
potential of translation to the clinic with additional improvements 
in the future (Wang et al., 2009). Similarly, the concentrations of 
miR-21, miR-17-5p, miR-106a, and miR-106b were significantly 
higher in gastric cancer patients than healthy controls, whereas 
let-7a was lower in gastric cancer patients. The levels of aberrantly 
expressing miRNAs were also significantly reduced in post-oper-
ative samples than pre-operative controls. These findings suggest 
that detection of circulating miRNAs may provide new comple-
mentary tumor markers for gastric cancer (Tsujiura et al., 2010).
The identification of a patient who is prognostically good or 
poor is very important for the development of effective treatment 
approach (Cho, 2011a). Recent findings have revealed a great poten-
tial of circulating miRNA signatures as molecular fingerprints to 
predict survival of cancer patients. Genome-wide serum miRNA-
expression analysis found that the levels of four miRNAs (miR-1, 
miR-30d, miR-486, and miR-499) were significantly associated with 
the overall survival of non-small cell lung cancer (NSCLC) patients. 
These four serum miRNA signatures may serve as an independent 
minimally invasive predictor for the overall survival of NSCLC 
(Hu et al., 2010). Moreover, the evaluation of plasma miRNAs also 
detected decreased levels of let-7f, miR-20b, and miR-30e-3p in the 
vesicles of NSCLC patients than healthy controls. The plasma levels 
of let-7f and miR-30e-3p were associated with overall survival and 
short disease-free survival, respectively. These results suggest that 
plasma vesicle-related miRNAs obtained by minimally invasive 
methods can serve as circulating tumor biomarkers of discrim-
inating and prognostic values (Silva et al., 2011). On the other 
hand, quantitative reverse transcription-polymerase chain reaction 
(qRT-PCR) analysis in CLL patients with chromosome 17p deletion 
also found that miR-21 expression levels were significantly higher 
in patients with poor overall survival, whereas lower miR-181b m
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conclusion
MicroRNA is a cutting-edge topic in the scientific and medical fields, 
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